489 related articles for article (PubMed ID: 28637103)
1. [The Development of Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease].
Kwon OS; Kim JH; Kim JH
Korean J Gastroenterol; 2017 Jun; 69(6):348-352. PubMed ID: 28637103
[TBL] [Abstract][Full Text] [Related]
2. [Clinical features of non-alcoholic fatty liver disease in cryptogenic hepatocellular carcinoma].
Rim MY; Kwon OS; Ha M; Kim JS; Ko KI; Kim DK; Jang PK; Han JY; Park PH; Jung YK; Choi DJ; Kim YS; Kim JH
Korean J Gastroenterol; 2014 May; 63(5):292-8. PubMed ID: 24870301
[TBL] [Abstract][Full Text] [Related]
3. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
4. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
Zoller H; Tilg H
Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
[TBL] [Abstract][Full Text] [Related]
5. Hepatocellular carcinoma development in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Is it going to be the "Plague" of the 21st century? A literature review focusing on pathogenesis, prevention and treatment.
Argyrou C; Moris D; Vernadakis S
J BUON; 2017; 22(1):6-20. PubMed ID: 28365930
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic fatty liver disease-associated hepatocellular carcinoma in a hepatitis B virus-endemic area.
Yoon CH; Jin YJ; Lee JW
Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):1090-1096. PubMed ID: 29847489
[TBL] [Abstract][Full Text] [Related]
7. Clinical Patterns and Outcome of Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
Ahn SY; Kim SB; Song IH
Can J Gastroenterol Hepatol; 2020; 2020():4873875. PubMed ID: 32566546
[TBL] [Abstract][Full Text] [Related]
8. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period.
Pais R; Fartoux L; Goumard C; Scatton O; Wendum D; Rosmorduc O; Ratziu V
Aliment Pharmacol Ther; 2017 Nov; 46(9):856-863. PubMed ID: 28857208
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD.
Reeves HL; Zaki MY; Day CP
Dig Dis Sci; 2016 May; 61(5):1234-45. PubMed ID: 26921078
[TBL] [Abstract][Full Text] [Related]
10. Hepatocarcinogenesis in non-alcoholic fatty liver disease in Japan.
Tokushige K; Hashimoto E; Kodama K
J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():88-92. PubMed ID: 24251711
[TBL] [Abstract][Full Text] [Related]
11. The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives.
Pennisi G; Celsa C; Giammanco A; Spatola F; Petta S
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717576
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology and Etiologic Associations of Non-alcoholic Fatty Liver Disease and Associated HCC.
Liu K; McCaughan GW
Adv Exp Med Biol; 2018; 1061():3-18. PubMed ID: 29956203
[TBL] [Abstract][Full Text] [Related]
13. The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma.
Lewinska M; Santos-Laso A; Arretxe E; Alonso C; Zhuravleva E; Jimenez-Agüero R; Eizaguirre E; Pareja MJ; Romero-Gómez M; Arrese M; Suppli MP; Knop FK; Oversoe SK; Villadsen GE; Decaens T; Carrilho FJ; de Oliveira CP; Sangro B; Macias RIR; Banales JM; Andersen JB
EBioMedicine; 2021 Nov; 73():103661. PubMed ID: 34740106
[TBL] [Abstract][Full Text] [Related]
14. Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice?
Edenvik P; Davidsdottir L; Oksanen A; Isaksson B; Hultcrantz R; Stål P
Liver Int; 2015 Jul; 35(7):1862-71. PubMed ID: 25524812
[TBL] [Abstract][Full Text] [Related]
15. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.
Bertot LC; Adams LA
Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):179-187. PubMed ID: 30791782
[TBL] [Abstract][Full Text] [Related]
16. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
Perumpail RB; Wong RJ; Ahmed A; Harrison SA
Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
[TBL] [Abstract][Full Text] [Related]
17. Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice.
Yokohama K; Fukunishi S; Ii M; Nakamura K; Ohama H; Tsuchimoto Y; Asai A; Tsuda Y; Higuchi K
Int J Mol Med; 2016 Nov; 38(5):1499-1506. PubMed ID: 28025996
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for non-alcoholic fatty liver disease are common in patients with non-B non-C hepatocellular carcinoma in India.
David D; Raghavendran A; Goel A; Bharath Kumar C; Kodiatte TA; Burad D; Abraham P; Ramakrishna B; Joseph P; Ramachandran J; Eapen CE
Indian J Gastroenterol; 2017 Sep; 36(5):373-379. PubMed ID: 28975595
[TBL] [Abstract][Full Text] [Related]
19. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease.
Degasperi E; Colombo M
Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):156-164. PubMed ID: 28404072
[TBL] [Abstract][Full Text] [Related]
20. [Non-alcoholic fatty liver disease and hepatocellular carcinoma - 2016].
Pár A; Pár G
Orv Hetil; 2016 Jun; 157(25):987-94. PubMed ID: 27287838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
